CSBio CSBio

X
[{"orgOrder":0,"company":"Eisai","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eisai Enters Industry-Academia-Government Joint Research Agreement","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"JAPAN","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Eisai"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$1,890.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sosei Announces Second Novel Drug Candidate from Its Multi-Target Drug Discovery Collaboration with Pfizer has Started Clinical Trials","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"JAPAN","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Sosei Heptares"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            This candidate is the eighth GPCR-targeted drug candidate to enter clinical trials originating from Sosei Heptares’ StaR® technology and structure-based drug design (SBDD) platform.

            Lead Product(s): Undisclosed

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Pfizer Inc

            Deal Size: $1,890.0 million Upfront Cash: Undisclosed

            Deal Type: Collaboration September 28, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            In this project, Eisai aims at creating a Japan-originated therapeutic drug for systemic lupus erythematosus (SLE) through industry-academia-government collaboration, using its in-house discovered new oral Toll-Like Receptor (TLR) 7/8 inhibitor E6742.

            Lead Product(s): E6742

            Therapeutic Area: Immunology Product Name: E6742

            Highest Development Status: Phase I Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement July 13, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY